Table 2 Primers used in the experiments

Name	Sequence of primer (5'-3')	Note
NsylCBL1a-2F	CCATGGGCTGTTTCCAGTCTACAGC	correspond to 1-23 nt of *NsylCBL1*a CDS sequence, and *Nco*I restriction site introduced
NsylCBL1a-1R	TTAGGTAGCCATCTCATCAACTTC	antisense to 619-642 nt of *NsylCBL1*a CDS sequence; and insert *NsylCBL1a* by *Bam*H I restriction site of pMD19-T to construct the pGADT7 vector.
NsyCBL1b-2F	CCATGGGCTGCTTTCATTCTAAGG	correspond to 1-22 nt of *NsyCBL1b* CDS sequence, and *Nco*I restriction site introduced
NsyCBL1b-1R	TTATGTAGCAACTTCATCAACT	antisense to 621-642 nt of *NsylCBL1*b CDS sequence; and insert *NsylCBL1b* by *Bam*H I restriction site of pMD19-T to construct the pGADT7 vector
NsylCBL2-2F	CCATGGATGTTGCAGTGCCTAGACGG	correspond to 1-20 nt of *NsylCBL2* CDS sequence, and *Nco*I restriction site introduced
NsylCBL2-1R	TCAGGTATCCTCAACTCTGGAATG	antisense to 652-675 nt of *NsylCBL2* CDS sequence; and insert *NsylCBL2* by *Bam*H I restriction site of pMD19-T to construct the pGADT7 vector
NsylCBL3-2F	CCATGGATGTCGCATTGTTTAGAGGGGAT	correspond to 1-22 nt of *NsylCBL3* CDS sequence, and *Nco*I restriction site introduced
NsylCBL3-1R	GGATCCTCAGGTATCCGGGACTCTTG	antisense to 659-678 nt of *NsylCBL3* CDS sequence, and *Bam*H I restriction site introduced
NsylCBL4a-1F	CCATGGGCTGCTTTCACTCC	correspond to 1-18 nt of *NsylCBL4a* CDS sequence, and *Nco*I restriction site introduced
NsylCBL4a-1R	TTAGACTTCCAAATCTTCAACC	antisense to 621-642 nt of *NsylCBL4a* CDS sequence; and insert *NsylCBL4a* by *Bam*H I restriction site of pMD19-T to construct the pGADT7 vector
NsylCBL5-1F	CCATGGGCTGTGCTTTAAGAAAGCAAGA	correspond to 1-26 nt of *NsylCBL5* CDS sequence, and *Nco*I restriction site introduced
NsyCBL5-1R	GGATCCTCAGAAATCCTTGTAAATCTCATC	antisense to 618-642 nt of *NsylCBL5* CDS sequence, and *Bam*H I restriction site introduced
NsylCBL6-2F	CCATGGAGTGAATTGTTGCGATTCTTGTTTATATG	correspond to 1-28 nt of *NsylCBL6* CDS sequence, and *Nco*I restriction site introduced
NsylCBL6-2R	GGATCCTCACGTATCTTCAACTTGAGAG	antisense to 614-641 nt of *NsylCBL6* CDS sequence, and *Bam*H I restriction site introduced
NsyCBL9-2F	CCATGGGCTGTTTTAGTTCTACAGC	correspond to 1-23 nt of *NsylCBL9* CDS sequence, and *Nco*I restriction site introduced
NsyCBL9-3R	GGATCCGGTACCTCAAGTAGCTACTTC	antisense to 627-641 nt of *NsylCBL9* CDS sequence, and *Bam*H I restriction site introduced
CBL10-1-2F	AAGCTTCCATGGATTCAACCCGCG	correspond to 1-14 nt of *NsylCBL10* CDS sequence, and *Nco*I restriction site introduced
CBL10-1-3R	GGTACCGGATCCCAACAAATGGCTTTTC	antisense to 664-679 nt of *NsylCBL10* CDS sequence, and *Bam*H I restriction site introduced

Note: The underlined sequences represent the restriction sites